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ABSTRACT
Background. Time to surgery (TTS) has been suggested
to have an association with mortality in early-stage breast
cancer.
Objective. This study aims to determine the association
between TTS and preoperative disease progression in
tumor size or nodal status among women diagnosed with
clinical T1N0M0 ductal breast cancer.
Methods. Women diagnosed with clinical T1N0M0 ductal
breast cancer who had breast-conserving surgery as their
first definitive treatment between 2010 and 2016
(n = 90,405) were analyzed using the National Cancer
Database. Separate multivariable logistic regression
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models for hormone receptor (HR)-positive and HR-negative patients, adjusted for clinical and demographic
variables, were used to assess the relationship between TTS
and upstaging of tumor size (T-upstaging) or nodal status
(N-upstaging).
Results. T-upstaging occurred in 6.76% of HR-positive
patients and 11.00% of HR-negative patients, while
N-upstaging occurred in 12.69% and 10.75% of HR-positive and HR-negative patients, respectively. Among HRpositive patients, odds of T-upstaging were higher for
61–90 days TTS (odds ratio [OR] 1.18, 95% confidence
interval [CI] 1.05–1.34) and C91 days TTS (OR 1.47, 95%
CI 1.17–1.84) compared with B30 days TTS, and odds of
N- upstaging were higher for C91 days TTS (OR 1.35,
95% CI 1.13–1.62). No association between TTS and either
T- or N-upstaging was found among HR-negative patients.
Other clinical and demographic variables, including grade,
tumor location, and race/ethnicity, were associated with
both T- and N-upstaging.
Conclusion. TTS C61 and C91 days was a significant
predictor of T- and N-upstaging, respectively, in HR-positive patients; however, TTS was not associated with
upstaging in HR-negative breast cancer. Delays in surgery
may contribute to measurable disease progression in
T1N0M0 ductal breast cancer.

Breast cancer is one of the most commonly diagnosed
malignancies in the U.S.1,2 Staging at the time of diagnosis
is an independent prognostic factor in breast cancer,3 and
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survival rates steeply decline with increasing stage.4
Clinical stage is determined by radiographic measurement
of lesion size and disease spread to regional lymph nodes
and distant organs.5 Subsequent pathologic staging is based
on pathologic evaluation of tumor size and lymph node
involvement in surgically resected lesions, along with the
presence or absence of distant metastasis. Accordingly,
upstaging is defined as a progressive discordance of tumor
size, lymph node involvement, or distant metastasis
between clinical and pathologic staging. Current literature
suggests that dense breast tissue, palpable tumors, high
grade, pleomorphic calcifications, lymphovascular invasion, and use of core-needle rather than vacuum-assisted
biopsy are factors significantly associated with upstaging of
ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).6–8 A recent study suggested that prolonged
time from diagnosis to surgery (time to surgery [TTS]) C30
days is also associated with increased risk of upstaging
from DCIS to IDC (median 38 days, range 30–365 days).8
Additional studies have demonstrated delay in surgery in
early-stage breast cancer is associated with increased
mortality risk,9,10 raising the question of whether TTS is
also associated with measurable disease progression;
however, previous studies examining the association
between TTS and disease progression of invasive disease
have not found a link.11–13 This study aims to analyze the
association between upstaging and TTS by hormone
receptor (HR) status among women diagnosed with clinical
T1N0M0 ductal breast cancer who received breast-conserving surgery (BCS) as their first treatment. We also
analyzed other clinical and sociodemographic factors
associated with upstaging.
METHODS
Cohort
Women with clinical T1N0M0 ductal breast cancer
diagnosed by needle or incisional biopsy between 2010 and
2016 who received BCS as their first definitive treatment
were selected from the National Cancer Database (NCDB).
The NCDB is a joint project of the Commission on Cancer
(CoC) of the American College of Surgeons and the
American Cancer Society, and all data used in this study
were de-identified and met the criteria for exempt review
by the University of Oklahoma Health Sciences Center
Institutional Review Board (IRB# 7446). Women were
selected based on a clinical stage of T1N0M0,14 ductal
histology (International Classification of Diseases for
Oncology, Third Revision [ICD-O-3] codes 8022, 8035,
8500–8503, 8523), and receipt of BCS as their first treatment (Surgery of the Primary Site codes 19–24). Only
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cases diagnosed and treated, all or in part, at the reporting
facility were included in the final cohort. Cases with previous, concurrent, or subsequent malignancies, missing
clinical or pathologic staging, no biopsy or missing biopsy
information, neoadjuvant treatment, non-definitive surgery
(i.e. excisional biopsy) as their first treatment, or with
incomplete covariate data, were excluded (Fig. 1). Patients
with pathologic stage IV disease were excluded from
analyses due to the likelihood of undetected metastases
present at the time of diagnosis rather than new clinically
detectable metastases developing within the preoperative
timeframe (n = 36, 0.03%). Additionally, the number of
patients downstaged to pathologic in situ only tumors was
insufficient (n = 47, 0.04%) to be examined as a separate
outcome and was excluded from the analyses. Finally,
patients who did not have any nodes examined or who had
an unknown number examined were excluded due to discordance with the National Comprehensive Cancer
Network/American Joint Committee on Cancer guidelines
for determining pathologic stage.14,15

Exclusion Scheme for Study Cohort
Women diagnosed with breast cancer
NCDB, 2010-2016 (n=1,569,607)
Breast cancer 1st and only cancer (n=1,184,867)
Exclusions:
• Neoadjuvant treatment, non-definitive
surgery, no or missing biopsy information,
TTS ≤7 or >180 days (n=498,472)
• Not diagnosed or treated at least partially
at reporting facility (n=355,578)
• Clinical Stage 0 or II-IV, node positive, non
-IDC histology, pathologically DCIS or
metastatic (n=202,440)
• Mastectomy and other non-breast
conserving treatment (n=30,384)
• Missing covariate data (n=7,588)

HR-positive
patients
(ER and/or PR +)
n=81,122

HR-negative
Patients
(ER-/PR -)
n=9,283

FIG. 1 Exclusion scheme. NCDB National Cancer Database, TTS
time to surgery, IDC invasive ductal carcinoma, DCIS ductal
carcinoma in situ, HR hormone receptor, ER estrogen receptor, PR
progesterone receptor

Disease Progression by Surgical Delay

Exposure
TTS was defined as the number of days between
definitive diagnosis by biopsy and surgery and categorized
by monthly intervals (i.e. B 30, 31–60, 61–90, and C 91
days). Patients who received surgery in 7 or fewer days
were excluded from our study since receipt of surgery
within 1 week of definitive diagnosis is unlikely in the
modern setting (n = 1,824, 1.97%) and may be clinically
reflective of greater medical urgency or unique circumstances. Additionally, patients with TTS over 6 months
(180 days) were excluded from the study cohort due to
exceptional delay (n = 127, 0.14%).
Outcome
Upstaging was defined by two separate measures:
T-upstaging as an increase in tumor size from clinical T1 to
pathologic T2 or higher, and N-upstaging as a change in
nodal status from clinical N0 to pathologic N1 or higher.
Definitions
The cohort was grouped into two categories according to
HR status (i.e. estrogen and/or progesterone)—HR-positive
or HR-negative. HER2 status was determined using collaborative staging site-specific factor,15,16 which
summarizes the results of immunohistochemistry and geneamplification test (fluorescence in situ hybridization or
chromogenic in situ hybridization) scoring of HER2 status
as HER2-positive, HER2-borderline/equivocal, or HER2negative. Patient race/ethnicity was categorized as White,
Black, Hispanic, or other (Asian, Pacific Islander, American Indian/Eskimo/Aleutian), and age was dichotomized
by the average age of menopausal onset (B50 or
[50 years), since menopausal status at the individual level
was unavailable in the NCDB. Number of nodes examined
during surgery was categorized as 1, 2–3, 4–5, or C6.
Location of tumor was classified according to ICD-O-3
codes as nipple/central portion (50.0, 50.1), upper inner
quadrant (50.2), lower inner quadrant (50.3), upper outer
quadrant (50.4), lower outer quadrant (50.5), axillary tail
(50.6), or overlapping/other (50.8, 50.9).
Statistics
Patient characteristics were summarized by frequency
and proportion for both T- and N-upstaging. For continuous variables, the median, range, first quartile (Q1), and
third quartile (Q3) were used to summarize their distributions. Separate binary multivariable logistic regression
models were used to examine the association between TTS
and the outcome of either T- or N-upstaging, adjusted for
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dichotomized age, HER2 status, grade, tumor location,
patient race/ethnicity, Charlson comorbidity score, and, for
N-upstaging models, number of nodes examined. All statistical analyses were conducted using SAS software
version 9.4 (SAS Institute, Inc., Cary, NC, USA), and
graphs were generated using JMP version 14.
RESULTS
Composition of the Cohort
Following exclusions, the final cohort included 90,405
patients diagnosed with clinical T1N0M0 ductal carcinoma
who received BCS between 2010 and 2016, with 89.73%
(n = 81,122) HR-positive and 10.26% (n = 9,283) HRnegative. The median age at diagnosis was 64 years (range
23–90; Q1: 56; Q3: 71) among HR-positive patients and 62
years (range 24–90; Q1: 55; Q3: 70) among HR-negative
patients. The median TTS was 28 days (Q1: 20; Q3: 40)
among HR-positive patients and 27 days (Q1: 19; Q3: 38)
among HR-negative patients, and the proportion of TTS
was also similar in both groups (B 30 days: 56.82%; 31–60
days: 36.88%; 61–90 days: 5.17%; C 91 days: 1.13%, in
HR-positive patients; B 30 days: 60.09%; 31–60 days:
34.31%; 61–90 days: 4.61%; C 91 days: 0.99%, in HRnegative patients). The proportion of T-upstaging grew
with increasing TTS, from 6.6% of those with TTS B 30
days to 9.59% of those with TTS C 91 days among HRpositive patients; and from 10.77% of those with TTS B 30
days to 13.04% of those with TTS C 91 days among HRnegative patients (Table 1). Overall, 6.76% (n = 5,483) of
HR-positive patients and 11.00% (n = 1,021) of HR-negative patients experienced upstaging from clinical T1 to
pathologic T2 or higher (Table 1). The highest rates of
T-upstaging in HR-positive patients were seen in tumors
that were grade 3 or higher (13.99%), HER2-positive
(9.80%), or located in the nipple/central portion of the
breast (8.99%) and among Hispanic patients (9.06%). HRnegative patients who were B 50 years of age (15.50%) or
Hispanic (15.26%), or who had a Charlson Comorbidity
Index C 2 (13.32%) were more frequently T-upstaged
(Table 1). With regard to N-upstaging, 12.69%
(n = 10,298) of HR-positive cases and 10.75% (n = 998)
of HR-negative cases were upstaged from clinical N0 to
pathologic N1 or higher. The proportion of patients
N-upstaged also grew with increasing intervals of TTS, i.e.
from 12.69% of HR-positive patients with B 30 days TTS
to 16.34% of patients with C 91 days TTS upstaged, and
from 10.81% of HR-negative patients with B 30 days TTS
to 16.30% of patients with C 91 days TTS. N-upstaging
was most prevalent in HR-positive cases that were HER2positive (14.83%), located in the axillary tail (18.06%) or
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age (16.98%) [Table 1]. Higher proportions of N-upstaging
occurred among HR-negative patients with tumors located
in the nipple/central portion of the breast (14.78%), had
C 6 lymph nodes examined (35.45%), or who were Hispanic (14.79%) or B 50 years of age (13.32%) [Table 1].
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Adjusting for the clinical and sociodemographic characteristics detailed in Table 1, HR-positive patients
experienced a statistically significant increase in T-upstaging among those with 61–90 days TTS (OR 1.18, 95%
CI 1.05–1.34) and C 91 days TTS (OR 1.47, 95% CI
1.17–1.84) compared with those with B 30 days TTS,
while those with 31–60 days TTS did not experience a
significant increase in risk (OR 1.04, 95% CI 0.98–1.1)
[Fig. 2a]. However, TTS of any interval [30 days was not
associated with T-upstaging in HR-negative patients after
multivariable adjustment (Fig. 2b). Similarly, TTS was
significantly associated with N-upstaging at C 91 days
TTS (OR 1.35, 95% CI 1.12–1.62) compared with TTS
B 30 days among HR-positive patients (Fig. 2c), but not at
31–60 or 61–90 days TTS. There was not a significant
association between TTS and N-upstaging in the HR-negative model (Fig. 2d).
Other clinical and demographic factors were also associated with T- and N-upstaging, with statistical significance
and effect sizes different according to HR status. Higher
histologic grade was significantly associated with T-upstaging (OR 2.31, 95% CI 2.15–2.48 in grade 2; OR 4.58,
95% CI 4.21–4.98 in grade 3 or higher) and N-upstaging
(OR 1.58, 95% CI 1.50–1.66 in grade 2; OR 1.80, 95% CI
1.68–1.92 in grade 3 or higher) in HR-positive patients,
while among HR-negative patients, only grade 3 or higher
was significantly associated with T-upstaging (OR 1.72,
95% CI 1.01–2.93) [Table 2]. HER2 status was not significantly associated with T-upstaging, but was associated
with higher odds of N-upstaging among HR-negative
patients (OR 1.63, 95% CI 1.01–2.62 in HER2-borderline;
OR 0.51, 95% CI 1.27–1.78 in HER2-positive) [Table 2].
HR-positive tumors located in the nipple/central portion of
the breast had higher odds of T-upstaging (OR 1.28, 95%
CI 1.11–1.47) and N-upstaging (OR 1.41, 95% CI
1.27–1.57) than those located in the upper outer quadrant
[Table 2]. The likelihood of N-upstaging grew substantially
with increasing number of nodes examined. Patients who
had [ 6 removed/examined were more likely to be N-upstaged compared with those with only 1 node examined
regardless of HR status (OR 6.17, 95% CI 5.77–6.59 in
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FIG. 2 Association between
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1.5
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OR

HR-positive patients; OR 9.6, 95% CI 7.71–11.97 in HRnegative patients). In terms of demographic variables,
patients B 50 years of age had statistically significant
higher odds of T-upstaging (OR 1.18, 95% CI 1.09–1.28 in
HR-positive patients; OR 1.42, 95% CI 1.18–1.72 in HRnegative patients) and N-upstaging (OR 1.26, 95% CI
1.18–1.34 in HR-positive patients; OR 1.19, 95% CI
0.98–1.46 in HR-negative patients), regardless of HR status. Additionally, HR-positive patients with a Charlson
comorbidity index score of C 2 were significantly more
likely to be T-upstaged (OR 1.28, 95% CI 1.11–1.46) or
N-upstaged (OR 1.13, 95% CI 1.01–1.27) than those
without comorbidities (Table 2). Finally, regardless of HR
status, Hispanic patients experienced significantly higher
odds of T-upstaging (OR 1.28, 95% CI 1.13–1.45 in HRpositive patients; OR 1.40, 95% CI 1.06–1.85 in HR-negative patients) and N-upstaging (OR 1.27, 95% CI
1.15–1.40 in HR-positive patients; OR 1.38, 95% CI
1.02–1.86 in HR-negative patients). Similarly, Black HRpositive patients had higher odds of T-upstaging (OR 1.10,
95% CI 1.00–1.12) and N-upstaging (OR 1.10, 95% CI
1.02–1.18) than White patients (Table 2).
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DISCUSSION
Multivariable analyses of clinical T1N0M0 ductal breast
carcinoma patients who received BCS as their first definitive treatment revealed that the preoperative period (TTS)
was a significant predictor of disease progression in HRpositive patients, with 8% and 30% higher odds of T-upstaging at C 61 and C 91 days TTS, respectively, and 17%
higher odds of N-upstaging at C 91 days TTS. Studies
demonstrating a positive association between TTS and
mortality risk among patients with early-stage breast cancer,9,10 as well as a positive association between TTS and
upstaging of DCIS,8,13 raised the question of whether a
prolonged preoperative interval is associated with measurable disease progression. However, earlier studies have
not shown an association between TTS and upstaging in
invasive disease.11–13 An institutional study enrolling
clinically node-negative invasive breast cancer patients
(n = 635) demonstrated no association between time from
radiographic screening (mammography or sonography) to
surgery (median 21 days, range 1–132 days) with tumor
size or lymph node upstaging.11 Similarly, a comparison of
serial sonographic images at the time of initial diagnosis
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TABLE 2 Odds ratios for upstaging by clinical or sociodemographic characteristics
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and the day prior to surgery (median 31, range 8–78 days)
among 323 unifocal invasive breast cancer patients concluded that time between diagnosis and surgery [30 days
was not associated with tumor growth compared with time
B 30 days.12 This discrepancy may be attributable to
several factors, including shorter median or range of TTS
compared with our cohort (median 28 days in HR-positive
and 27 days in HR-negative; range 8–180 days), differing
classifications of TTS intervals, and inclusion of a broader
range of disease (stage, histology, and HR status). A more
recent study for the analysis of cT1-2N0 disease using the
NCDB (n = 279,090) showed that TTS had no association
with upstaging from clinical to pathologic prognostic stage
after adjustment; however, a trend of increasing upstaging
with prolonged TTS was seen among patients with cT1N0
disease in unadjusted analysis.13 One of the key differences
in our study is the use of a selective cohort of anatomic
cT1N0M0 ductal breast carcinoma patients who received
BCS as their first definitive treatment. Since mastectomy is
indicated for higher-risk disease (e.g. multifocal, multicentric, family history/genetics, etc.), patients who
underwent mastectomy were excluded due to differing
disease nature from those who receive BCS.13 In fact,
mastectomy was a significant predictor of disease upstaging in other studies.8,13 Similarly, patients with non-ductal
histology such as lobular carcinoma were excluded based
on predicted ambiguity of radiographic tumor size measurement reported in lobular carcinoma in situ.13 Lastly,
our cohort was categorized by TTS intervals of B 30,
31–60, 61–90, and C 91 days, with B 30 days TTS as the
reference category based on the observed statistically significant difference in overall mortality observed in each
30-day interval beyond B 30 days TTS.9 Overall, our data
highlight the importance of minimizing the preoperative
period to avoid the potential risk of disease progression in
HR-positive T1N0M0 ductal breast carcinoma.
Similar to upstaging trends reported in DCIS patients,
our analysis recapitulated a positive association between
upstaging and HER2 positivity, higher histology grade, and
younger age in T1N0M0 ductal carcinomas.17–20 Our
multivariable analysis showed that the nipple/central portion of the breast is significantly associated with increased
risk of upstaging relative to tumors located in the upper
outer quadrant for HR-positive tumors, presumably due to
the convergence of mammary ducts at the nipple-areolar
complex.21 The high density of fibroglandular tissue in this
region results in heightened radiographic opacity that poses
a challenge for sensitivity of mammographic detection in
retroareolar masses.21 Another clinically significant finding
of our study was age-related differences in upstaging. This
may be attributable in part to the higher prevalence of
aggressive subtypes or higher breast density among premenopausal women.19,22 Breast Imaging Reporting and
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Data System (BI-RADS) category 4 and 5 disease (as
opposed to category 3) is reported to be consistently and
significantly associated with upstaging of DCIS to invasive
breast cancer.6 Greater breast density, defined by a higher
percentage of radiographically dense epithelial and stromal
tissue in the breast as opposed to radiographically lucent
adipose tissue, both decreases mammographic sensitivity
for detecting breast masses and is an independent risk
factor for breast cancer regardless of the method by which
it is detected.23,24 A cross-sectional meta-analysis of over
11,000 women found that mammographic density
decreased with increasing age in both premenopausal and
postmenopausal women, with the greatest reduction in
mammographic density occurring at the time of menopausal transition.25
During the coronavirus disease 2019 (COVID-19) pandemic, 15% of cancer patients reported that their inpatient
surgical procedures had been affected.26 Given the concern
over the potentially negative survival impact of excessive
surgical delays, the COVID-19 Breast Cancer Consortium
published guidelines for operative prioritization. T1N0
estrogen receptor (ER)-positive/HER2-negative patients
are categorized into priority level C1 and recommended
neoadjuvant endocrine therapy (NET) in the context of
delayed operation27 based on the comparable efficacy and
overall survival rate of NET to adjuvant endocrine therapy
in the GRETA trial.28 A NCDB cohort study showed that
postmenopausal women with cT2-4c ER-positive breast
cancer (n = 2,294) treated with NET were 1.6 times more
likely to undergo BCS.29 Similarly, Minami et al. recently
demonstrated that in patients with cT1-2N0 breast cancer,
NET use did not impact stage or overall survival, supporting its safe use as a means of delaying surgery in
patients with ER-positive breast cancer during the COVID19 pandemic.13 Additionally, randomized studies have
demonstrated an overall response rate to NET of[50% and
an NET-induced conversion rate to BCS of [30%.30–32
The duration and type of NET have been suggested to
affect the response rate.33 While the incremental benefit of
NET is evident at a therapy duration of up to 8 months,32,34
studies of short treatment duration showed limited efficacy,35 as the response rate of breast cancer to NET is
slow. The P024 trial, during which postmenopausal women
with ER-positive stage II–III breast cancers (n = 228)
underwent treatment with neoadjuvant letrozole or
tamoxifen for 4 months prior to surgery, revealed a significantly higher overall response rate in patients treated
with letrozole (55% vs. 36%).30,36 Despite efficacy in
downsizing tumors and the favorable safety profile of
NET,31,36 the rates of disease progression during NET
range from about 5–25%,30–32 partly due to molecular
mechanisms that contribute to endocrine resistance.37–40
Since the primary focus of randomized trials using NET
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has largely been to downstage clinical stage T2 or higher
tumors,30,34,35 its effect on T1N0 breast cancer remains
unknown. Since the current study focused on patients who
underwent surgery as their primary cancer treatment and
excluded NET-treated cases, our data are not generalizable
to those who were treated with NET and experienced
extended surgical delays during the COVID-19 pandemic.
Further follow-up retrospective studies to evaluate the
impact of NET on T1N0 HR-positive breast cancer patients
using a dataset with capacity for data adjustment for NET
responses will be critical in gaining insight into breast
cancer management.
The current study has several strengths and limitations.
The large cohort size, along with the ability to adjust for
multiple tumor properties and demographic characteristics
with exclusion of potentially confounding subpopulations,
provides, for the first time, a valuable context for understanding of the association between surgical delays and
measurable disease progression of both tumor size and
nodal status in IDCs. To our surprise, after multivariable
analysis, TTS-dependent upstaging remained significant in
HR-positive patients, but not in HR-negative patients, even
though the likelihood of T-upstaging among HR-negative
patients was nearly double that among HR-positive patients
(11.0% vs. 6.8%). Additionally, there was no interaction
between TTS and HER2 status in any of the models, suggesting both luminal A (HR-positive/HER2-negative) and
B (HR-positive/HER2-positive) subtypes are likely to be
affected by a delay in surgery. In light of this insight, which
seems opposed to current understanding of HR-positive
disease as slow-proliferating and HR-negative disease as
rapidly-proliferating,41,42 it is critical to address the
mechanism underlying HR-specific TTS-associated
upstaging. One main limitation includes the varying
detection sensitivity43–45 of radiographic images utilized
for clinical staging. Accurate tumor size measurement by
mammogram and sonogram remains a challenge, especially in dense breast tissue,46,47 lobular carcinomas,48 and
lesions under the nipple/areolar complex.21 Since the type
of imaging modality and BI-RADS score are unavailable in
the NCDB, further investigation with such variables to
address the ambiguity of radiographic imaging is necessary
to further determine the contribution of TTS to upstaging.
Additionally, although we used a clinically selective subpopulation for our analysis, characterized by small earlystage tumors, to substantiate TTS-associated upstaging of
invasive breast cancer, this does not negate the possibility
of TTS-associated upstaging in higher-stage disease or
disease with non-ductal histology.
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CONCLUSION
Overall, preoperative disease progression of clinical
T1N0M0 ductal carcinoma patients was largely
attributable to intrinsic tumor biology, including subtype,
histology grade, and tumor location, and to demographic
factors, including age, race/ethnicity, and comorbidities.
However, TTS presented a modifiable factor that was significantly associated with both T- and N-upstaging among
HR-positive clinical T1N0M0 ductal carcinoma patients,
underscoring the importance of timely surgery.
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